Video-Tumorboard PLUS

NCT06980740 | Recruiting

• 2 other identifiers: BO ff (Multi)-EK-160120252025-275-b-S
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 3

Brief Summary

In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.

Conditions

Malignant Melanoma; Telemedicine

Keywords

Malignant Melanoma; Telemedicine

Outcome Measures

Primary Outcomes (1)

• Presentation of external patients in the video-tumorboard

  Increase in the proportion of external patients in the video-tumorboard

  Day 365

Secondary Outcomes (5)

• Increase in the proportion of external patients invited to a clinical study

  Day 365

• Adherence to tumorboard recommendations for external patients

  Up to two weeks after inclusion

• Offer of supportive therapies by the comprehensive cancer center

  Up to two days after inclusion

• Duration of the transmission of the tumorboard recommendations

  Up to two weeks after inclusion

• "Time to integration" into palliative care

  Once per patient within two weeks after transmission of the tumorboard recommendation if applicable

Study Arms (2)

1

Retrospective

2

Prospective

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

As part of the vTB+ study, an evaluation of the video tumor board is to be carried out for as broad a section of the population as possible. Women of childbearing potential with and without contraception make up a relevant proportion of the population. Participation in the study is not associated with physical interventions, so that the contraceptive status of fertile participants is irrelevant. Even in the case of pregnancy, participation in the study would be harmless. The exclusion of women of childbearing potential with and without contraception from the vTB+ study would therefore represent a gender-based disadvantage.

You may qualify if:

• The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
• Minimum age 18 years
• Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
• Malignant melanoma from stage IIB
• Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
• In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
• has a medical license
• has dermatological patients who are eligible to be presented in the vTB+

You may not qualify if:

• Patients will be excluded from the study if they meet the following criteria:
• Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
• No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.

Sponsors & Collaborators

• University Hospital Muenster: lead
• Deutsche Krebshilfe e.V., Bonn (Germany): collaborator
• University Hospital, Bonn: collaborator
• University Hospital Dresden: collaborator

Study Sites (3)

Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn

Bonn, 53127, Germany

NOT YET RECRUITING

Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden

Dresden, 01099, Germany

RECRUITING

Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster

Münster, 48149, Germany

NOT YET RECRUITING

MeSH Terms

Conditions

Melanoma

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Philipp Lenz, MD

  Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Philipp Lenz, MD

CONTACT

+49 251 83 43745; philipp.lenz@ukmuenster.de

Friedegund Meier, MD

CONTACT

+49 351 4583677; friedegund.meier@ukdd.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2025
• First Posted: May 20, 2025
• Study Start: May 1, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): May 31, 2027
• Last Updated: May 20, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL

Locations

DE (3)